Sign In
Pricing

Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc

3002 (Harmonized System 1992 for 4-digit)

2022
World Trade $330BRnk 11 / 1218
2022
Top Exporter | Top Importer $47.3B | $69.9BIreland | United States
2022
Product Complexity 1.32Rnk 80 / 1033
2021 - 2022
Export Growth (CAGR) -0.8%Rnk 900 / 1218
2022
Share of World Trade 1.39%Rnk 11 / 1218

About

Overview This page contains the latest trade data of Vaccines, blood, antisera, toxins and cultures. In 2022, Vaccines, blood, antisera, toxins and cultures were the world's 11th most traded product, with a total trade of $330B. Between 2021 and 2022 the exports of Vaccines, blood, antisera, toxins and cultures decreased by -0.8%, from $333B to $330B. Trade in Vaccines, blood, antisera, toxins and cultures represent 1.39% of total world trade.

Vaccines, blood, antisera, toxins and cultures are a part of Pharmaceutical products. They include Antisera and other blood fractions, Vaccines, human use, Blood, toxins, cultures, medical use, nes, Vaccines, veterinary use, except foot and mouth, and Vaccines, foot and mouth disease, veterinary use.

Exports In 2022 the top exporters of Vaccines, blood, antisera, toxins and cultures  were Ireland ($47.3B), Belgium ($47.1B), United States ($46.8B), Switzerland ($46.7B), and Germany ($45.5B).

Imports In 2022 the top importers of Vaccines, blood, antisera, toxins and cultures were United States ($69.9B), Germany ($36B), Belgium ($20.7B), Japan ($19.6B), and China ($16.5B).

Ranking Vaccines, blood, antisera, toxins and cultures ranks 80th in the Product Complexity Index (PCI).

Description Human blood is used to provide oxygen and nutrients to the tissues and to carry away waste products from the tissues. Animal blood prepared for therapeutic, prophylactic or diagnostic uses is used to study blood-borne diseases and to provide antibodies that are used in the diagnosis of diseases. Antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, are used in the diagnosis of diseases. Vaccines, toxins, cultures of micro-organisms (excl. yeasts) and similar products are used in the prevention and treatment of diseases.

Latest Trends

Latest Data

View
Flow
Y-AXIS SCALE

The following visualization shows the latest trends on Vaccines, blood, antisera, toxins and cultures. Countries are shown based on data availability.

For a full breakdown of trade patterns, visit the trend explorer or the product in country profile.

Explore Latest Trends

* Trade values are converted to USD using each month's exchange rate. For December 2023 data, the exchange rate from December 30, 2023 is used.

Subscribe today to OEC pro and access the latest data

Sign Up

Historical Data

Exporters and Importers

Top Origin (2022)Ireland$47.3B
Top Destination (2022)United States$69.9B

In 2022 Vaccines, blood, antisera, toxins and cultures were the world's 11th most traded product (out of 1,218).

In 2022, the top exporters of Vaccines, blood, antisera, toxins and cultures were Ireland ($47.3B), Belgium ($47.1B), United States ($46.8B), Switzerland ($46.7B), and Germany ($45.5B).

In 2022, the top importers of Vaccines, blood, antisera, toxins and cultures were United States ($69.9B), Germany ($36B), Belgium ($20.7B), Japan ($19.6B), and China ($16.5B).

Explore Visualizations

Exporters of Vaccines, blood, antisera, toxins and cultures (2022)
[Click to Select a Country]

Importers of Vaccines, blood, antisera, toxins and cultures (2022)
[Click to Select a Country]

Market Dynamics

Color
Top Origin Growth (2021 -  2022)Ireland$10.4B
Top Destination Growth (2021 -  2022)United States$16.5B

Between 2021 and 2022, the exports of Vaccines, blood, antisera, toxins and cultures grew the fastest in Ireland ($10.4B), Switzerland ($6.52B), Sweden ($1.88B), Italy ($1.75B), and United States ($1.26B).

Between 2021 and 2022, the fastest growing importers of Vaccines, blood, antisera, toxins and cultures were United States ($16.5B), Netherlands ($6.01B), Japan ($4.96B), China ($4.21B), and Switzerland ($3.79B).

Explore Visualizations

Exporters of Vaccines, blood, antisera, toxins and cultures (2021 - 2022)

Importers of Vaccines, blood, antisera, toxins and cultures (2021 - 2022)

Market Concentration

Value

This chart shows the evolution of the market concentration of exports of Vaccines, blood, antisera, toxins and cultures.

In 2022, market concentration measured using Shannon Entropy, was 3.74. This means that most of the exports of Vaccines, blood, antisera, toxins and cultures are explained by 13 countries.

Explore Visualizations

Value of Exports in Vaccines, blood, antisera, toxins and cultures

Net Trade

TOP NET EXPORTER (2022)Ireland$42.3B
TOP NET IMPORTER (2022)United States$23B

This map shows which countries export or import more of Vaccines, blood, antisera, toxins and cultures. Each country is colored based on the difference in exports and imports of Vaccines, blood, antisera, toxins and cultures during 2022.

In 2022, the countries that had a largest trade value in exports than in imports of Vaccines, blood, antisera, toxins and cultures were Ireland ($42.3B), Switzerland ($31.7B), Belgium ($26.4B), Germany ($9.48B), and South Korea ($2.88B).

In 2022, the countries that had a largest trade value in imports than in exports of Vaccines, blood, antisera, toxins and cultures were United States ($23B), Japan ($15.7B), China ($12.9B), Canada ($6.83B), and Brazil ($4.4B).

Net Trade (2022)

Disaggregation

Value

In 2022, the world most traded Vaccines, blood, antisera, toxins and cultures, disaggragated by their HS6 level were Blood, toxins, cultures, medical use, nes ($228B), Vaccines, human use ($89.2B), Antisera and other blood fractions ($9.17B), and Vaccines, veterinary use, except foot and... ($4.05B)

HS6 Disaggregation for Vaccines, blood, antisera, toxins and cultures (2022)
[Click to Select]

Country Comparison

Flow
Measure
Ranking

This visualization shows the countries that have an important ratio of their trade related to Vaccines, blood, antisera, toxins and cultures.
It is possible to select the main countries that export or import Vaccines, blood, antisera, toxins and cultures in the world, or by continent, as well as select the measure of interest.

Top 10 Exporters Countries of Vaccines, blood, antisera, toxins and cultures by percentage of total exports

Potential Exports

Potential Exports

Flow
View
TOP EXPORT POTENTIALUnited Kingdom+ $503M
TOP IMPORT POTENTIALGermany+ $168M

Vaccines, blood, antisera, toxins and cultures’s highest export potential is United Kingdom. With an export gap of $503M.  Vaccines, blood, antisera, toxins and cultures’s highest import potential is Germany with an import gap of $168M.

See methodology.

Subscribe today to OEC pro and access the latest data

Sign Up

Product Complexity

Diversification Frontier

Specialization

The Complexity-Relatedness diagram compares the risk and the strategic value of a product's potential export opportunities. Relatedness is predictive of the probability that a country increases its exports in a product. Complexity, is associated with higher levels of income, economic growth potential, lower income inequality, and lower emissions.

Relatedness vs Country Complexity (2022)

Related Products

This visualization shows products that are likely to be exported by countries that export Vaccines, blood, antisera, toxins and cultures.

Country by Relatedness

The following visualization shows the relatedness of Vaccines, blood, antisera, toxins and cultures to countries. Higher relatedness values ​​indicate greater knowledge, which predicts a greater probability of exporting that product in the future.

Relative Relatedness by Country (2022)

Keep Exploring

Have questions, comments, or concerns?
Send us an e-mail: support@oec.world
Follow @OECtoday on
Created, Designed, and Developed by:
In collaboration with
About the OECPrivacy PolicyTerms